Regulation And Legal
Verastem Oncology Gains 4% on FDA Fast Track
FDA granted Fast Track Designation to Verastem’s KRAS G12D inhibitor VS‑7375 for advanced NSCLC, prompting a 4% after‑hours stock rise.
The designation targets adult patients with KRAS G12D‑mutated un
